UroNav Fusion Biopsy: Leading Detection of Prostate Cancer
Holland Hospital and Western Michigan Urological Associates are proud to be the first in the region to offer UroNav Fusion Biopsy, an innovative new technology that offers more a precise and accurate detection of prostate cancer. UroNav Fusion Biopsy offers early detection, an active surveillance, and improved outcomes for prostate cancer.
Prostate Cancer – What You Need to Know:
Prostate cancer is the most common cancer in men, affecting one in seven, and is the second leading cause of death. There are two categories of men who are likely to derive the greatest benefit from UroNav. First are those who’ve had one or more negative prostate biopsies in the past where there is continued concern of prostate cancer. The second are men who choose active surveillance as a management strategy.
How UroNav Fusion Biopsy Works:
- UroNav is a cutting-edge diagnostic tool that may become a new standard of care for the early detection and active surveillance of prostate cancer.
- UroNav advances the “active surveillance” approach of suspicious lesions in the prostate. A Magnetic Resonance Imaging (MRI) of the prostate is performed at the hospital, the urologist then fuses the MRI images with ultrasound images during the biopsy to provide a real-time visualization of the suspected lesions.
- This GPS-like tracking technology identifies suspicious areas that can be targeted during an office-based prostate biopsy, which may improve the accuracy and precision of those biopsies.
If you have any questions regarding the UroNav Fusion Biopsy or if you think it may be right for you, our team of professionals are here to answer any questions to help you make an informed decision. We at Western Michigan Urological Associates want to work with you to find the best option for you and your family. Ask Your Primary Care Provider for a Referral.
